Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Itonaga, Hidehiro  [Clear All Filters]
2024
Kurosawa S, Shimomura Y, Ishiyama K, Fuse K, Shimazu Y, Doki N, Uchida N, Tanaka M, Takahashi S, Sakurai M, et al. Updated comparable efficacy of cord blood transplantation for chronic myelomonocytic leukaemia: a nationwide study. Bone Marrow Transplant. 2024.
2023
Fuji S, Inoue Y, Makiyama J, Nakano N, Ito A, Kawakita T, Eto T, Suehiro Y, Itonaga H, Sawayama Y, et al. The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy. Bone Marrow Transplant. 2023.
Shimomura Y, Kitamura T, Konuma T, Nakaya Y, Doki N, Sawa M, Nakamae H, Eto T, Nishida T, Ohigashi H, et al. Hematopoietic stem cell transplantation from haploidentical offspring donors using post-transplant cyclophosphamide versus human leukocyte antigen-matched siblings in older patients with myelodysplastic syndrome. Am J Hematol. 2023.
Nakaya Y, Koh H, Konuma T, Shimomura Y, Ishiyama K, Itonaga H, Hino M, Doki N, Nishida T, Ohigashi H, et al. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide versus HLA-Matched Unrelated Donor Transplantation for Myelodysplastic Syndrome. Transplant Cell Ther. 2023.
Shimomura Y, Komukai S, Kitamura T, Tachibana T, Kurosawa S, Itonaga H, Tsukamoto S, Doki N, Katayama Y, Ito A, et al. The prognosis and risk factors for patients with complex karyotype myelodysplastic syndrome undergoing allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2023.
Itonaga H, Kato T, Sawayama Y, Katsuoka S, Furumoto T, Matsumoto N, Sasaki D, Yamada Y, Hashimoto M, Fujioka M, et al. RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL. Leuk Lymphoma. 2023:1-4.
Konuma T, Itonaga H, Ishiyama K, Doki N, Uchida N, Sawa M, Katayama Y, Tanaka M, Ueda Y, Onizuka M, et al. Should a matched sibling donor still be considered the primary option for allogeneic hematopoietic cell transplantation in patients over 50 years of age with myelodysplastic syndrome?. Bone Marrow Transplant. 2023.
Konuma T, Itonaga H, Shimomura Y, Fujioka M, Aoki K, Uchida N, Onizuka M, Jinguji A, Tanaka M, Ueda Y, et al. Single-unit unrelated cord blood transplantation versus HLA-matched sibling transplantation in adults with advanced myelodysplastic syndrome: A registry-based study from the adult MDS working group of the Japanese society for transplantation and cellular . Hematol Oncol. 2023.
2022
Fujioka M, Itonaga H, Furumoto T, Sakaki C, Sakamoto H, Kato T, Horai M, Taguchi M, Sawayama Y, Taguchi J, et al. Clinical features of non-infectious pulmonary complications after donor lymphocyte infusion in post-transplant patients: The Nagasaki transplant group experience. Transpl Immunol. 2022:101707.
Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, et al. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Hematol Oncol. 2022.
2021
Sakamoto H, Itonaga H, Sawayama Y, Kojima A, Chiwata M, Fujioka M, Kitanosono H, Horai M, Miyazaki T, Shiraishi H, et al. Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy. Int J Hematol. 2021.
Fujioka M, Itonaga H, Furumoto T, Kasai S, Sakamoto H, Kitanosono H, Kato T, Horai M, Sato S, Sawayama Y, et al. The response-guided ATG treatment provides a survival benefit and KPS recovery for patients with steroid refractory acute GVHD: The Nagasaki Transplant Group Experience. Transpl Immunol. 2021:101417.
2020
Sakamoto H, Itonaga H, Sawayama Y, Furumoto T, Fujioka M, Chiwata M, Toriyama E, Kasai S, Nakashima J, Horai M, et al. Treatment with Mogamulizumab or Lenalidomide for Relapsed Adult T-cell Leukemia/Lymphoma after Allogeneic Hematopoietic Stem Cell Transplantation: The Nagasaki Transplant Group Experience. Hematol Oncol. 2020.
2018
Itonaga H, Ota S, Ikeda T, Taji H, Amano I, Hasegawa Y, Ichinohe T, Fukuda T, Atsuta Y, Tanizawa A, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. Leuk Res. 2018;75:50-57.
Sakamoto H, Itonaga H, Sawayama Y, Taguchi J, Saijo T, Kuwatsuka S, Hashisako M, Kinoshita N, Oishi M, Doi H, et al. Primary Oral Mucormycosis Due to Rhizopus microsporus after Allogeneic Stem Cell Transplantation. Intern Med. 2018;57(17):2567-2571.
2014
Wong Y-F, Micklem CN, Taguchi M, Itonaga H, Sawayama Y, Imanishi D, Nishikawa S, Miyazaki Y, Jakt LMartin. Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome. Stem Cells Transl Med. 2014.